OFIX

Business Context and Reporting Period

Company: Orthofix International N.V. (Orthofix)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2000
Business Overview: Orthofix designs, develops, manufactures, and markets medical equipment for the orthopedic market, including external/internal fixation devices, bone growth stimulators, and vascular therapy products. The company operates globally with manufacturing facilities in the U.S., U.K., Italy, and the Seychelles.

Key Financial Metrics (Year Ended Dec 31, 2000)

Note: 2000 Net Income includes a significant non-recurring gain of approximately $38.0 million (pre-tax) from the settlement of litigation against Biomet/EBI.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 9% to $131.8 million, driven by a 15% increase in North American sales ($87.4 million). International sales decreased 2% nominally but would have increased 4% on a constant dollar basis.
• Profitability Surge: Net income jumped 247% to $44.8 million. This was primarily due to the $38.0 million pre-tax gain from the EBI litigation settlement. Excluding non-recurring items, net income was $14.9 million (EPS $1.07) compared to $12.9 million (EPS $0.97) in 1999.
• Liquidity Improvement: Cash and cash equivalents increased by $40.8 million to $50.5 million, largely due to the litigation settlement proceeds. Operating cash flow increased to $56.3 million from $8.5 million.
• Debt Reduction: Total debt decreased to $10.8 million from $14.2 million, with loan repayments of $4.5 million offset by reduced borrowings under lines of credit.
• Acquisitions: Acquired assets of Kinesis Medical Inc. for $7.3 million (Orthotrac product) and a 10% equity interest in OPED AG for $2.5 million.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• Management expects to invest approximately $4.6 million in capital expenditures in 2001 to support business expansion.
• Direct operations commenced in Germany, Austria, and Switzerland in 2001 following the termination of the Sulzer Inc. distribution agreement.
• Stimulation products marketing is expanding into Europe in 2001.

Risks and Contingencies:

• Litigation: Pending patent infringement suit against Kinetic Concepts Inc. (KCI) regarding the A-V Impulse System; trial expected in late 2001. Also, a government inquiry (HHS/DoD) regarding coding for reimbursement of stimulation products and EZ Brace, which could have a material adverse effect.
• Regulatory: Dependence on FDA and foreign regulatory approvals; potential for delays or rejections.
• Third-Party Payors: Risk of reimbursement denials or price challenges by government programs and private insurers.
• Intellectual Property: Risks related to patent validity, infringement claims, and protection of trade secrets.
• Foreign Exchange: Exposure to currency fluctuations, though the company attempts to match non-dollar revenues and expenses.

Investor Verification Checklist

• Non-Recurring Income: Verify the sustainability of earnings by excluding the $38 million litigation gain; core operating income remained relatively flat compared to 1999.
• Government Inquiry: Monitor the outcome of the HHS/DoD investigation into Medicare/Medicaid coding for stimulation products, as this could impact future revenue recognition.
• KCI Litigation: Track the status of the patent infringement suit against Kinetic Concepts Inc., including potential damages or injunctions.
• International Expansion: Assess the success of the transition from distributor-based to direct operations in Germany, Austria, and Switzerland.
• Debt Covenants: Review the restrictive covenants on the $10 million Term Note, specifically the limitation on transferring assets from Orthofix Inc. to the parent company.